Amgen gets orphan drug designation for anemia treatment

Amgen (NASDAQ:AMGN) has received an orphan drug designation for its Nplate (romiplostim) in treating aplastic anemia.

That will mean seven years’ market exclusivity if approved for the treatment.

Shares have been on a roll, up 12.2% over the past month and up 40.7% over the past six months.

https://seekingalpha.com/news/3522717-amgen-gets-orphan-drug-designation-anemia-treatment